Key numbers for Freshii’s Q4/17 had already been released in late January, with same store sales for the Toronto-based company up by 6.4 per cent in Q4 and 5.5 per cent for fiscal 2017. Freshii opened 25 net new stores in Q4, along with six closures and nine e-store openings (the company has 370 locations in the Americas and Europe).
Those numbers are in line with Johnston’s forecast, as were revenue of $5 million and adjusted EBITDA of $2.1 million for Q4 and adjusted EBITDA for fiscal 2017 of $7.2 million.
FRII began trading on the TSX in February of 2017, with the stock having lost half of its value over the past year. But management says things are looking up.
“We have learned a lot about operating in the public markets and have made progress towards driving our mission and building the start of an omni-channel brand,” says Matthew Corrin, Freshii Chairman and CEO in a press release today. “Our team’s focus on improving as each quarter has progressed is noticeable, and we are determined to carry that positive momentum into 2018.”
Johnston judges the investment impact of the Q4. “We rate Freshii a ‘Hold’ with a $7.00 target price, which is based on 14x our 2018 EBITDA estimate,” says the analyst.
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and $130.00 target on Graham Corporation (Graham Corporation Stock Quote, Chart,… [Read More]
Beacon Securities analyst Doug Cooper says iFabric’s (iFabric Stock Quote, Chart, News, Analysts, Financials TSX:IFA) medical scrubs opportunity is being… [Read More]
Beacon Securities analyst Russell Stanley reiterated his “Buy” rating and street-high $88.00 target on MDA Space (MDA Space Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu raised his target on Hammond Power Solutions (Hammond Power Solutions Stock Quote, Chart, News,… [Read More]
RBC senior economist Claire Fan says Canada’s September job losses were concentrated among younger workers and should not be overread.… [Read More]
Roth Capital Partners analyst Adam Walsh says a third controlled celiac disease dataset supporting IL-15 blockade increases the potential value… [Read More]